Product Name :
JND3229
Description:
JND3229 is a highly potent and fourth-generation EGFRC797S reversible inhibitor with IC50 value of 5.8 nM, and also potently suppressed EGFRL858R/T790M and EGFRWT with IC50 values of 30.5 and 6.8 nM.
CAS:
2260886-64-2
Molecular Weight:
617.18
Formula:
C33H41ClN8O2
Chemical Name:
N-((1r, 4r)-4-(3-(2-chlorophenyl)-7-(3-methyl-4-(4-methylpiperazin-1-yl)phenylamino)-2-oxo-3, 4-dihydropyrimido[4, 5-d]pyrimidin-1(2H)-yl)cyclohexyl)propionamide
Smiles :
CN1CCN(CC1)C1=CC=C(C=C1C)NC1=NC2=C(CN(C3=CC=CC=C3Cl)C(=O)N2[C@@H]2CC[C@H](CC2)NC(=O)CC)C=N1
InChiKey:
WVLWGBZNXIVAKC-YOCNBXQISA-N
InChi :
InChI=1S/C33H41ClN8O2/c1-4-30(43)36-24-9-12-26(13-10-24)42-31-23(21-41(33(42)44)29-8-6-5-7-27(29)34)20-35-32(38-31)37-25-11-14-28(22(2)19-25)40-17-15-39(3)16-18-40/h5-8,11,14,19-20,24,26H,4,9-10,12-13,15-18,21H2,1-3H3,(H,36,43)(H,35,37,38)/t24-,26-
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥360 days if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
JND3229 is a highly potent and fourth-generation EGFRC797S reversible inhibitor with IC50 value of 5.8 nM, and also potently suppressed EGFRL858R/T790M and EGFRWT with IC50 values of 30.5 and 6.8 nM.|Product information|CAS Number: 2260886-64-2|Molecular Weight: 617.18|Formula: C33H41ClN8O2|Chemical Name: N-((1r, 4r)-4-(3-(2-chlorophenyl)-7-(3-methyl-4-(4-methylpiperazin-1-yl)phenylamino)-2-oxo-3, 4-dihydropyrimido[4, 5-d]pyrimidin-1(2H)-yl)cyclohexyl)propionamide|Smiles: CN1CCN(CC1)C1=CC=C(C=C1C)NC1=NC2=C(CN(C3=CC=CC=C3Cl)C(=O)N2[C@@H]2CC[C@H](CC2)NC(=O)CC)C=N1|InChiKey: WVLWGBZNXIVAKC-YOCNBXQISA-N|InChi: InChI=1S/C33H41ClN8O2/c1-4-30(43)36-24-9-12-26(13-10-24)42-31-23(21-41(33(42)44)29-8-6-5-7-27(29)34)20-35-32(38-31)37-25-11-14-28(22(2)19-25)40-17-15-39(3)16-18-40/h5-8,11,14,19-20,24,26H,4,9-10,12-13,15-18,21H2,1-3H3,(H,36,43)(H,35,37,38)/t24-,26-|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : 12.{{Flutamide} site|{Flutamide} Androgen Receptor|{Flutamide} Purity & Documentation|{Flutamide} In Vivo|{Flutamide} custom synthesis|{Flutamide} Epigenetic Reader Domain} 5 mg/mL (20.{{Tazemetostat} site|{Tazemetostat} Apoptosis|{Tazemetostat} Purity & Documentation|{Tazemetostat} In stock|{Tazemetostat} supplier|{Tazemetostat} Epigenetics} 25 mM)|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.PMID:32310531 |Shelf Life: ≥360 days if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|References:|Lu X, et al. Discovery of JND3229 as a New EGFRC797S Mutant Inhibitor with In Vivo Monodrug Efficacy. ACS Med Chem Lett. 2018 Oct 8;9(11):1123-1127.Products are for research use only. Not for human use.|
